Filing Flows › Organogenesis Holdings (ORGO) › Q2 2026 › vs Q1 2026
Organogenesis Holdings (ORGO) Q2 2026 vs Q1 2026 (quarter over quarter)
Organogenesis Holdings's revenue rose $6.5M (+18%) from $37.2M in Q1 2026 to $43.8M in Q2 2026. The biggest changes: Product +$6.6M (+18%); Grant −$28K (-3%).
Organogenesis Holdings, Q2 2026: revenue $43.8M (-57% year over year), operating margin -116.5%, net loss $96.3M, operating cash flow −$31.7M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Product | $42.8M | $36.2M | $6.6M | +18% |
| Grant | $950K | $978K | −$28K | -3% |
| Revenue | $43.8M | $37.2M | $6.5M | +18% |
| Net loss | $96.3M | $53.2M | $43.1M | +81% |
| Costs & expenses | $140M | $106M | $34.0M | +32% |
| Operating costs | $94.7M | $106M | −$11.4M | -11% |
| Income tax | $45.4M | −$15.3M | $60.7M | — |
| Research & development | $18.3M | $15.2M | $3.1M | +21% |
| SG&A | $54.0M | $65.2M | −$11.2M | -17% |
| Other operating costs | $22.5M | $25.8M | −$3.3M | -13% |
| Operating cash sources | $96.3M | $53.2M | $43.1M | +81% |
| Depreciation & amortization | $3.7M | $4.2M | −$506K | -12% |
| Share-based compensation | $3.1M | $3.6M | −$584K | -16% |
| Working capital & other | $57.9M | $66.5M | −$8.6M | -13% |
| Cash used in operations | $31.7M | −$21.1M | $52.8M | — |
| Net loss absorbed | $96.3M | $53.2M | $43.1M | +81% |
Questions
How much did Organogenesis Holdings's revenue grow quarter over quarter in Q2 2026?
Organogenesis Holdings's revenue rose $6.5M (+18%) from $37.2M in Q1 2026 to $43.8M in Q2 2026.
What drove Organogenesis Holdings's revenue change in Q2 2026?
Product +$6.6M (+18%); Grant −$28K (-3%).